Altimmune, Inc.
For the period ended Dec 31, 2025. Filed Mar 6, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 6, 2026
ALT$1.94-8.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| | |
|---|---|
| Report of Independent Registered Public Accounting Firm — Ernst & Young LLP (PCAOB ID: 42) | 90 |
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | 92 |
| Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2025 and 2024 | 93 |
| Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2025 and 2024 | 94 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2025 and 2024 | 95 |
| Notes to Consolidated Financial Statements | 96 |
| 1. Nature of Business and Organization | 96 |
| 2. Summary of Significant Accounting Policies | 96 |
| 3. Fair Value Measurement | 102 |
| 4. Property and Equipment, Net | 104 |
| 5. Leases | 104 |
| 6. Accrued Expenses and Other Current Liabilities | 105 |
| 7. Term Loan | 105 |
| 8. Other Noncurrent Liabilities | 107 |
| 9. Stockholders’ Equity | 107 |
| 10. Stock-Based Compensation | 108 |
| 11. Employee Benefit Plans | 111 |
| 12. Income Taxes | 111 |
| 13. Net Loss Per Share | 114 |
| 14. Commitments and Contingencies | 114 |
| 15. Segment Information | 115 |
| 16. Subsequent Events | 115 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.